Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop)

Surbhi Sidana, Leyla Shune, Luciano Costa, Roberto Mina, Rafal Slowik, Jianming He, João Mendes, Jackie Kwong, Maren Gaudig, Seina Lee, Mukta Sharma, Rakesh Popat, Cyrille Touzeau

Blood (2025) 146 (Supplement 1): 5768.

https://doi.org/10.1182/blood-2025-5768

Published: 2025

Journal Articles

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Blood (2025) 146 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2025-2282

Published: 2025

Journal Articles

Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial

Rakesh Popat, Robert Cicero, Andrew Hall, Alexandra Welsh, Charlotte Pawlyn, Ceri Bygrave, Dean Smith, Simona Degli Esposti, Daniel Larkin, Gordon Cook, Matthew Jenner, Martin Kaiser, Lydia Lee, Rashmi Chandrashekar, Michael Nathan, Heena Patel, Sadie Roberts, Sarah Brown, Christopher Parrish

Blood (2025) 146 (Supplement 1): 4065.

https://doi.org/10.1182/blood-2025-4065

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Rakesh Popat, Katarina Uttervall, Aurore Perrot, Hila Magen, Vitaliy Mykytiv, Carmine Liberatore, Elena Zamagni, Matteo Claudio Da Vià, Elisabetta Antonioli, Markus Hansson, Danielle Greer, Peter Hu, Eric Aeby, Krystof Subrt, Nicholas Francella, Diptendu Santra, Natalia Martin Suñe, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 4573.

https://doi.org/10.1182/blood-2025-4573

Published: 2025

Journal Articles

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5825.

https://doi.org/10.1182/blood-2025-5825

Published: 2025

Journal Articles

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Blood (2025) 146 (Supplement 1): 5821.

https://doi.org/10.1182/blood-2025-5821

Published: 2025

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

Blood (2025) 146 (Supplement 1): 98.

https://doi.org/10.1182/blood-2025-98

Published: 2025

Journal Articles

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Simon Harrison, Caroline Hasselbalch Riley, Hira Mian, Andrew Spencer, Noa Lavi, Laura Paris, Jana Mihalyova, Rakesh Popat, Monika Szarejko, Sebastian Grosicki, Kihyun Kim, Irwindeep Sandhu, Sammy Chebon, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Kerstin Trunzer, Ameet Mishra, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 252.

https://doi.org/10.1182/blood-2025-252

Published: 2025

Journal Articles

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2025-4588

Published: 2025

Journal Articles

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2025-4173

Published: 2025

Journal Articles

Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study

Thomas LeBlanc, Rakesh Popat, C. Kennedy, Josh Coulter, Lewis Kopenhafer, William You, Kathleen Beusterien, David Hughes, Guido Nador, Joseph C Cappelleri, Marco Dibonaventura, Mohsena Sumaya, Patrick Hlavacek

Blood (2025) 146 (Supplement 1): 2631.

https://doi.org/10.1182/blood-2025-2631

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Blood (2025) 146 (Supplement 1): 2302.

https://doi.org/10.1182/blood-2025-2302

Published: 2025

Journal Articles

Ensuring equitable access to bispecific antibodies in multiple myeloma: Findings from the emmbrace patient and public involvement and engagement (PPIE) sessions.

Dunsi Bolarinwa, Rakesh Popat, Chantelle Hughes, Pinkie Chambers

Blood (2025) 146 (Supplement 1): 6186.

https://doi.org/10.1182/blood-2025-6186

Published: 2025

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (9): 1051–1064.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Sikander Ailawadhi, Yelak Biru, Solène Clavreul, Maite San Miguel, Nicolas Cormier, Anna Sato, Cathy Zeanah, James Farrell, Erinn Hoag Goldman, Rakesh Popat

Blood (2024) 144 (Supplement 1): 3658.

https://doi.org/10.1182/blood-2024-208007

Published: 2024

Journal Articles

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Hira Mian, Carlyn Rose Tan, Sireesha Asoori, Rakesh Popat, Nadine Abdallah, Saurabh Chhabra, Ricardo D. Parrondo, Gregory R Pond, Thomas Martin, Brian G.M. Durie, Yi Lin

Blood (2024) 144 (Supplement 1): 704.

https://doi.org/10.1182/blood-2024-200877

Published: 2024

Journal Articles

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Ceri Bygrave, William Wilson, Rakesh Popat, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Michael A. Chapman, Ruth M de Tute, Selina J Chavda, Elizabeth H. Phillips, Maria del Mar Cuadrado, Fuad Fananapazir, Charlotte Tyson, Sumaiya Kamora, James D. Cavenagh, Roger G Owen, Kwee Yong

Blood (2024) 144 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2024-199514

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop)

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Ensuring equitable access to bispecific antibodies in multiple myeloma: Findings from the emmbrace patient and public involvement and engagement (PPIE) sessions.

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only